ICU Medical (NASDAQ:ICUI) Price Target Raised to $187.00 at Needham & Company LLC

ICU Medical (NASDAQ:ICUI) had its price objective hoisted by Needham & Company LLC from $165.00 to $187.00 in a report released on Friday, Marketbeat.com reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Several other research analysts have also recently weighed in on the stock. KeyCorp boosted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a report on Tuesday, July 21st. Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Sanford C. Bernstein lowered shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Piper Sandler cut their price objective on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, BTIG Research upped their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $192.80.

ICU Medical Price Performance

Shares of ICUI opened at $184.56 on Friday. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $192.85. The firm’s 50-day simple moving average is $151.64 and its two-hundred day simple moving average is $141.02. The stock has a market cap of $4.61 billion, a PE ratio of 156.41, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, beating the consensus estimate of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The company had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period in the prior year, the firm posted $2.10 EPS. ICU Medical’s revenue for the quarter was up .5% on a year-over-year basis. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Analysts anticipate that ICU Medical will post 6.51 earnings per share for the current fiscal year.

Insider Activity at ICU Medical

In other news, VP Virginia Ruth Sanzone sold 2,447 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the transaction, the vice president owned 19,460 shares of the company’s stock, valued at approximately $2,414,596.80. The trade was a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the sale, the director owned 7,960 shares in the company, valued at $978,363.60. This represents a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 2.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ICU Medical

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. bought a new stake in ICU Medical during the 2nd quarter valued at about $550,250,000. Deutsche Bank AG bought a new position in ICU Medical in the 2nd quarter worth about $4,302,000. Bank of New York Mellon Corp bought a new position in ICU Medical in the 2nd quarter worth about $26,966,000. Oppenheimer Asset Management Inc. purchased a new position in shares of ICU Medical during the second quarter worth approximately $347,000. Finally, Revolve Wealth Partners LLC bought a new stake in shares of ICU Medical during the second quarter valued at approximately $243,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical News Roundup

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.